Symcel is expanding its workforce to bring its patented technology to the clinical antimicrobial susceptibility testing (AST) markets. The technology, called calScreener, is a cell-based assay tool for real-time cell metabolism measurements.    The company says it is a key time in its strategic development and, with an increased global focus, Symcel forecasts that calScreener will become the gold standard for combination testing of antibiotics against multi-resistant bacteria within the ...